Thalidomide for previously untreated elderly patients with multiple myeloma: Meta-analysis of 1685 individual patient data from 6 randomized clinical trials

Blood

Volumn 118, Issue 5, 2011, Pages 1239-1247

  Fayers, Peter M ^a,b   Palumbo, Antonio ^c   Hulin, Cyrille ^d   Waage, Anders ^b,e   Wijermans, Pierre ^f   Beksaç, Meral ^g   Bringhen, Sara ^c   Mary, Jean Yves ^h   Gimsing, Peter ⁱ   Termorshuizen, Fabian ^j   Haznedar, Rauf ^k   Caravita, Tommaso ^l   Moreau, Philippe ^m   Turesson, Ingemar ⁿ   Musto, Pellegrino ^o   Benboubker, Lotfi ^p   Schaafsma, Martijn ^q   Sonneveld, Pieter ^j   Facon, Thierry ^r  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

^e TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^f HAGA HOSPITAL   (Netherlands)

^g ANKARA UNIVERSITY   (Turkey)

^h INSERM   (France)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

^j ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^k GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^l UNIVERSITY OF ROME TOR VERGATA   (Italy)

^m NANTES UNIVERSITY HOSPITAL   (France)

ⁿ LUND UNIVERSITY HOSPITAL   (Sweden)

^o IRCCS Centro di Riferimento Oncologico della Basilicata OECI Clinical Cancer Center Rionero in Vulture   (Italy)

^p CHU BRETONNEAU   (France)

^q MEDISCH SPECTRUM TWENTE   (Netherlands)

^r LILLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN; PREDNISONE; THALIDOMIDE;

AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

EID: 80051570906     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-341669     Document Type: Article

References (27)

1. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565-1571.
2. Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2006;132(5):584-593. (Pubitemid 43381591)
3. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367(9513):825-831. (Pubitemid 43363369)
4. Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008;112(8):3107-3114.
5. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594):1209-1218. (Pubitemid 47516593)
6. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009;27(22):3664-3670.
7. Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol. 2010;28(19):3160-3166.
8. Waage A, Gimsing P, Fayers PM, et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood. 2010;116(9):1405-1411.
9. Beksac M, Haznedar R, Firatli-Tuglular T, et al. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol. 2011;86(1):16-22.
10. Kapoor P, Rajkumar SV, Dispenzieri A, et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia. 2011;25:689-696.
11. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-3420.
12. Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842-854.
13. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-656.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-478.
15. Cox DR. Regression model and life-tables (with discussion). J Roy Stat Soc B. 1972;34(2):187-220.
16. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558. (Pubitemid 34746062)
17. Tudor Smith C, Williamson PR, Marson AG. Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. Stat Med. 2005;24(9):1307-1319. (Pubitemid 40585170)
18. Katsahian S, Latouche A, Mary J-Y, Chevret S, Porcher R. Practical methodology of metaanalysis of individual patient data using a survival outcome. Contemp Clin Trials. 2008;29(2):220-230. (Pubitemid 351248769)
19. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011]. Cochrane Collaboration, 2011. Available from www.cochranehandbook.org.
20. Rucker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol. 2008;8:79.
21. StataCorp. Stata Statistical Software, Release 11. College Station, TX: StataCorp LP; 2009.
22. Gutierrez RG. Parametric frailty and shared frailty survival. Stata J. 2002;2:22-44.
23. Harris R, Bradburn M, Deeks J, Harbord R, Altman D, Sterne J. Metan: fixed- and randomeffects meta-analysis. Stata J. 2008;8:3-28.
24. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA Trial. J Clin Oncol. 2010;28(13):2259-2266.
25. Palumbo A, Dimopoulos M, Delforge M, et al. A phase 3 study to determine the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients ≥ 65 years with newly diagnosed multiple myeloma (NDMM) [abstract]. Haematologica (EHAAnnual Meeting Abstracts). 2010;95(suppl 2):234. Abstract 0566.
26. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29-37.
27. Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111(8):3968-3977.